about
Molecular diagnostics is an important element in realization of personalized medicine. The Dx-Rx Institute is committed to work with companion diagnostics and drug-diagnostic codevelopment and has been involved in a number of collaborations with academic and commercial partners. Throughout the years, the Dx-Rx Institute has published a number of articles on molecular diagnostics, companion diagnostics and drug-diagnostic co-development and has taken part in different educational activities at several European universities. The Dx-Rx Institute was established in 2009 by Dr. Jan Trøst Jørgensen as an independent institution where research goes hand in hand with consultancy.Please visit the company profile at Linked
For more information on this book please visit the publisher’s website
news
- Twenty-five years with HER2 targeted therapy
- On September 21st, 2023, the Danish Society for Cyto- and Histochemistry will host a symposium on HER2 targeted cancer treatment in the Large Auditorium at Herlev Hospital. It is free to attend the symposium and program and registration are available at the link.
- Twenty-five years with Companion Diagnostics
- Companion Diagnostics will soon celebrate its 25th anniversary. Read the interview with Dr. Jan Trøst Jørgensen
- The Economist
- Read the Economist Impact Report entitled 'A digital renaissance? Health innovation shifts to the micro' with an interview of Jan Trøst Jørgensen
- Interview with Dr. Jan Trøst Jørgensen
- Read the interview by Fionnuala Lane, Hanson Wade, on the value that CDx development brings to todays healthcare system and drug development
- Roles of MET in Cancer Development and Treatment
- Dr. Jens Mollerup, Agilent Technologies and Dr. Jan Trøst Jørgensen, Dx-Rx Institute have been appointed as guest editors for a special issue of Cancers on the 'Roles of MET in Cancer Development and Treatment'
- WHINN 2021
- On September 23, 2021, Dr. Jan Trøst Jørgensen, Dx-Rx Institute will give a presentation at WHINN 2021 entitled, Twenty Years with Personalized Medicine: Past, Present, and Future.
- Danish Society for Personalised Medicine
- The Dx-Rx Institute will give a presentation at the Annual Symposium on September 8 at Hvidovre Hospital. See the program:
- Companion and Complementary Diagnostics
- Expert Review of Molecular Diagnostic have just published a special issue on Companion and Complementary Diagnostics where Dr. Jan Trøst Jørgensen, Dx-Rx Institute has acted as Guest Editor.
- Personalized Medicine
- Biopeople has established a working group in personalized medicine with Dx-Rx Institute as an active participant.
- Dx-Rx Institute celebrate the 20th anniversary of Personalized Medicine
- Read the April edition of the Biopeople Newsletter.
- New book on Companion and Complementary Diagnostics
- A new book on companion and complementary diagnostics edited by Dr. Jan Trøst Jørgensen will be published by Academic Press in May this year. The book gives an in-depth insight into the individual steps from the early biomarker discovery phase straight through to final regulatory approval as well as the clinical implementation.
- Diagnostics and Precision Medicine
- The Faculty of Science and Health, Dublin City University will soon offer a new postgraduate master program in Diagnostics and Precision Medicine. The program will focus on how diagnostics and therapeutics are revolutionizing healthcare and medicine by individualizing patient care. Dr. Jan Trøst Jørgensen, Dx-Rx Institute has been appointed as accreditation board member for this new important master program.
- Companion Diagnostics and Oncology Drug Development
- At the 10th Annual Meeting of the Danish Society for Pharmacology, January 17, 2018, a poster on Companion Diagnostics and Oncology Drug Development was presented. A copy of the abstract and the poster can be requested on: info@dx-rx.dk
- Medical Herald
- HER2 gene signal distribution patterns in gastroesophageal cancer described by Danish scientists
- More than 125.000 have viewed this research topic!
- More than 125.000 have viewed the research topic on Drug-Diagnostics Co-Development in Oncology published in Frontiers in Oncology
- ASCO 2017
- An abstract by JT Jørgensen, KB Nielsen, G Kjærsgaard et al. entitled 'HER2 amplification and gene signal distribution in gastroesophageal cancer', has been published in Journal of Clinical Oncology.
- Biomarkers as an emerging growth area in Denmark
- Dr. Jan Trøst Jørgensen has been appointed advisor to 'Biomarker as an emerging growth area' project.
- Editorial Board Member
- The Director of the Dx-Rx Institute, Dr. Jan Trøst Jørgensen, has been appointed member of the Editorial Board for World Journal of Gastrointestinal Oncology.
- Critical Path to TB Drug Regimens
- Based on an invitation from Bill & Melinda Gates Foundation, Dr. Jan Trøst Jørgensen will on March 22, 2017 give a keynote lecture on drug-diagnostic codevelopment at the Critical Path to TB Drug Regimens Workshop in Washington DC.
- Annals of Translational Medicine
- Dr. Jan Trøst Jørgensen, Dx-Rx Institute has been appointed member of the Editorial Board of Annals of Translational Medicine.
- Workshop on Companion Diagnostics
- On January 31, 2017, Dr. Jan Trøst Jørgensen will give a lecture entitled; 'Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives'. Please visit webpage of BIO PEOPLE for further details
- 4th Joint EFLM-UEMS Congress - 'Laboratory medicine at the clinical interface'
- At the 4th Joint EFLM-UEMS Congress, Warsaw, September 21-24th 2016, Dr. Jan Trøst Jørgensen will give a plenary lecture on the clinical application of companion diagnostics.
- Most read article in Expert Review of Molecular Diagnostics
- The article 'Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC' is currently the most read article in Expert Review of Molecular Diagnostics. The article can be downloaded for free from the journals website.
- Editorial Board Member
- The Director of the Dx-Rx Institute, Dr. Jan Trøst Jørgensen, has been appointed member of the Editorial Board for Expert Review of Molecular Diagnostics.
- Most read article in Expert Review of Molecular Diagnostics.
- The article 'Companion diagnostics: the key to personalized medicine' is currently the most read article in 'Expert Review of Molecular Diagnostics'. The article can be downloaded for free from the journals website.
- Companion Diagnostics for Cancer - Will NGS Play a Role?
- The rapid accumulation of new knowledge on tumor biology resulting from next-gen sequencing is forcing stakeholders to continually rethink companion diagnostics. Read the article by Patricia Fitzpatrick Dimond published in GEN with contributions from Elizabeth Mansfield and Patricia Keegen, US FDA; Mya Thomae, Illumina and Jan Trøst Jørgensen, Dx-Rx Institute.
- Finding the Right Patient for Your Drug
- Interview with Jan Trøst Jørgensen (Elsevier Life Science Solutions News)
- No Drug Designed For Me
- Whitepaper on precision medicines and drug development from Elsevier R&D Solutions, Pharma & Life Sciences. Interview with Interviews with Dr. Jean Cui, Dr. Herbert Köppen, Dr. Scott Lusher, and Dr. Jan Trøst Jørgensen.
- A comprehensive update on companion diagnostics
- A special focus issue of Expert Review of Molecular Diagnostics.
selected publications from the dx-rx institute
- Twenty-five years with HER2 targeted therapy
- Ann Transl Med 2024;12(3):53. doi: 10.21037/atm-23-153
- MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations
- Transl Lung Cancer Res. 2024; 13: 940-946
- The impact of companion diagnostic testing on medical decision making and IVD regulations
- Expert Rev Mol Diagn. 2024; 24: 245-247
- Twenty-five years with companion diagnostics
- Chin Clin Oncol. 2023; 12: 65
- The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug
- Oncology. 2023; 101:836-842
- The Different Roles of MET in the Development and Treatment of Cancer
- Cancers. 2023; 15: 5087
- Predictive biomarkers and personalized pharmacotherapy
- Expert Rev Mol Diagn. 2022; 22: 919922
- Predictive biomarkers in medical treatment
- Ugeskr Laeger. 2022; 184: V05220300
- Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs
- JCO Precis Oncol. 2022; 6: e2200100
- Companion Diagnostics and Predictive Biomarkers for MET Targeted Therapy in NSCLC
- Cancers. 2022; 14: 2150
- Oncology drug-companion diagnostic combinations
- Cancer Treat Res Commun. 2021;29:100492
- A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer
- Front Oncol. 2021 Jul 23;11:676939
- The current landscape of the FDA approved companion diagnostics
- Transl Oncol. 2021; 14: 101063
- Predictive biomarkers and clinical evidence
- Basic Clin Pharmacol Toxicol. 2021; 128: 642-648
- MET deletion is a frequent event in gastric/gastroesophageal junction/esophageal cancer: a cross-sectional analysis of gene status and signal distribution in 1,580 patients
- Ann Transl Med. 2021; 9: 225
- PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC
- Chin Clin Oncol. 2020; 9(4): 60
- Site-agnostic Biomarker-Guided Oncology Drug Development
- Expert Rev Mol Diagn. 2020; 20 (6): 583-592
- Companion and Complementary Diagnostics: An Important Treatment Decision Tool in Precision Medicine
- Expert Rev Mol Diagn. 2020; 20 (6): 557-559
- Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.
- Oncologist. 2019; 24(7): e432-e440
- A paradigm shift in biomarker guided oncology drug development
- Ann Transl Med. 2019; 7 (7): 148
- Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology
- Clin Pharmacol Ther. 2018; 103(6): 999-1008
- Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer
- Transl Lung Cancer Res. 2018; 7: S95-S99
- When biomarkers define a drug indication
- Expert Rev Mol Diagn. 2018; 18: 315-317
- The ESMO Precision Medicine Glossary
- Ann Oncol. 2018; 29(3): 781-782.
- Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer
- Ther Drug Monit. 2018; 40(1): 9-16.
- Detection of MET amplification in gastroesophageal tumor specimens using IQFISH.
- Ann Transl Med. 2017; 5(23): 458.
- Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
- J Cancer 2017; 8(9): 1517-1524
- Companion diagnostics - a tool to improve pharmacotherapy
- Ann Transl Med 2016; 4 (24): 482
- Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
- Trends Cancer 2016; 2: 706-712.
- Companion Diagnostics: From Biomarkers to Diagnostics
- Reference Module in Chemistry, Molecular Sciences and Chemical Engineering (Elsevier, 2016).
- The importance of predictive biomarkers in oncology drug development
- Expert Rev Mol Diagn 2016; 16: 807-809
- Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
- Expert Rev Mol Diagn. 2016; 16: 131-133
- Clinical application of companion diagnostics.
- Trends Mol Med 2015; 21: 405-407.
- Companion diagnostics: the key to personalized medicine.
- Expert Rev Mol Diagn 2015; 15: 153-156.
- Drug-diagnostics co-development in oncology
- Front Oncol 2014; 4: 208.
- Companion diagnostics for targeted cancer drugs
- Clinical and regulatory aspects. Front Oncol 2014; 4: 105
- The Role of HER2 in Gastric Cancer
- Biological and Pharmacological aspects. World J Gastroenterol 2014; 20: 4526-35
- A changing landscape for companion diagnostics
- Expect Rev Mol Diagn 2013; 13: 667-669.
- Companion Diagnostics in Oncology - current Status and Future Aspects
- Oncology 2013; 85:59-68.
- HER2 as a Prognostic Marker in Gastric Cancer - a Systematic Analysis of Data from the Literature
- J Cancer 2012; 3: 137-144
- A challenging drug development process in the era of personalized medicine
- Drug Discov Today 2011; 16: 891-897.
- Targeted HER2 Treatment in Advanced Gastric Cancer.
- Oncology 2010; 78: 26-33.
